HIV, Inflammation, and Cardiovascular Health: A Deep Dive

For individuals living with HIV, the challenges extend beyond managing the virus itself. A growing body of research highlights a significant link between HIV infection, chronic inflammation, and an increased risk of cardiovascular disease (CVD). This article explores the complex interplay between HIV, the immune system, and heart health, offering insights into the latest understanding of this critical comorbidity.

The Inflammatory Cascade in HIV

HIV directly impacts the body’s immune response, not just by weakening it, but similarly by triggering persistent inflammation. The virus attacks central control mechanisms of the immune system, leading to opportunistic infections, malignancies, and if untreated, death. Research indicates that even before significant immunodeficiency develops, many people with HIV experience morbidity from immune-based hypersensitivity diseases.

This inflammation isn’t simply a byproduct of fighting the virus; it’s a complex process involving both innate and adaptive immune systems. Cells of both systems contribute to systemic and vascular inflammation, creating a fertile ground for the development of CVD.

Monocytes and Cardiovascular Disease in HIV

Specific immune cells, like monocytes, play a crucial role in driving inflammation in people with HIV. Studies have focused on circulating monocytes – specifically non-classical (NCM) and intermediate monocytes (IM) – to understand their contribution to HIV-associated CVD.

Research involving women with and without HIV, and with varying degrees of subclinical CVD, revealed key insights:

• Gene expression in intermediate monocytes (IM) was largely unaffected by HIV or CVD alone. However, when both conditions coexisted, a distinct gene transcription signature emerged, which was reduced with lipid-lowering treatment.
• Non-classical monocytes (NCM) showed altered gene expression in individuals with HIV, regardless of CVD status.
• The most significant changes in gene expression were observed in NCM from those with both HIV and CVD.
• Upregulated genes in HIV-positive patients included potential targets for drug therapies, such as LAG3 (CD223).

These findings suggest that circulating monocytes may serve as potential viral reservoirs and that transcriptional changes are amplified in the presence of subclinical CVD.

Immune Activation and Arterial Injury

Persistent immune activation is a hallmark of HIV infection and is strongly linked to arterial injury. While advancements in antiretroviral therapy have significantly improved viral control, they haven’t completely eliminated the inflammatory burden. Studies demonstrate improvements in markers of immune activation and HIV replication, but the underlying inflammatory processes continue to contribute to cardiovascular risk.

Managing Cardiovascular Risk in People with HIV

Given the increased risk of CVD, proactive management is essential for individuals living with HIV. This includes:

• Antiretroviral Therapy (ART): Effective ART is the cornerstone of managing HIV and reducing inflammation.
• Lifestyle Modifications: Adopting a heart-healthy lifestyle – including a balanced diet, regular exercise, and smoking cessation – is crucial.
• Lipid Management: Addressing elevated cholesterol levels with appropriate medication, as evidenced by the impact of lipid-lowering treatment on the gene transcription signature observed in studies.
• Monitoring and Screening: Regular cardiovascular screenings are vital for early detection and intervention.

Future Directions

Ongoing research continues to unravel the intricate relationship between HIV, inflammation, and cardiovascular health. Investigating novel therapeutic targets, such as LAG3, and exploring the potential of allergen immunotherapy (AIT) in HIV-positive patients with allergies, offer promising avenues for improving long-term health outcomes. As life expectancies continue to increase with advancements in HIV treatment, addressing cardiovascular risk will remain a critical priority.